Company Performance - AngioDynamics reported a quarterly loss of $0.11 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and compared to a loss of $0.12 per share a year ago, indicating an earnings surprise of 26.67% [1] - The company posted revenues of $67.49 million for the quarter ended August 2024, missing the Zacks Consensus Estimate by 1.46%, and down from $78.68 million in the same quarter last year [1] - Over the last four quarters, AngioDynamics has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [1] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.10 on revenues of $71.22 million, and for the current fiscal year, it is -$0.41 on revenues of $284.81 million [4] - The estimate revisions trend for AngioDynamics is currently favorable, resulting in a Zacks Rank 1 (Strong Buy), suggesting that the shares are expected to outperform the market in the near future [4] Industry Context - The Medical - Instruments industry, to which AngioDynamics belongs, is currently in the top 24% of over 250 Zacks industries, indicating a strong performance potential [5] - Another company in the same industry, Integer, is expected to report quarterly earnings of $1.36 per share, reflecting a year-over-year change of +7.1%, with revenues anticipated to be $444.59 million, up 9.9% from the previous year [5][6]

Financial Performance - AngioDynamics achieved pro forma revenue growth of 1.1% year-over-year[3] - MedTech segment pro forma revenue grew by 8.7% year-over-year[3] - Auryon sales reached $13.7 million, a 24.9% increase year-over-year[3] - AlphaVac sales amounted to $2.2 million, reflecting a 21.1% year-over-year growth[3] - The company reported a pro forma Adjusted EBITDA loss of ($0.2) million, an improvement from ($1.1) million in Q1 FY24[3] - Full Year Net Sales guidance is $282 - $288 million[28] Product & Regulatory Milestones - The Auryon System received CE Mark approval in Europe[3] - An FDA submission was filed for NanoKnife prostate indication[3] - The RECOVER-AV clinical trial was initiated[3] - Cumulative sales of Auryon are over $140 million since its launch in September 2020[5] - FDA 510(k) & CE Mark for PE was received for AlphaVac in Q4 FY24[13]

[Financial & Operational Highlights](index=1&type=section&id=Financial%20%26%20Operational%20Highlights) AngioDynamics reported 1.1% pro forma net sales growth in Q1 FY2025, driven by Med Tech, while achieving key regulatory and clinical milestones Q1 FY2025 Pro Forma Net Sales Overview | Metric | August 31, 2024 | Pro Forma YoY Growth | | :--- | :--- | :--- | | Net Sales | $67.5 million | 1.1% | | Med Tech Net Sales | $28.0 million | 8.7% | | Med Device Net Sales | $39.5 million | (3.6)% | Q1 FY2025 Key Profitability Metrics | Metric | Value | | :--- | :--- | | GAAP Gross Margin | 54.4% | | GAAP Loss Per Share | $0.31 | | Adjusted Loss Per Share | $0.11 | - Key operational milestones include submitting the NanoKnife System for FDA 510(k) clearance for prostate tissue, receiving CE Mark approval for the Auryon System in Europe, and initiating the RECOVER-AV clinical trial[2](index=2&type=chunk) - The CEO highlighted a strong start to FY2025, driven by **over 20% growth in both Auryon and AlphaVac**, viewing the fiscal year as an inflection point for the business[3](index=3&type=chunk) [Detailed Financial Performance (Q1 FY2025)](index=1&type=section&id=Detailed%20Financial%20Performance%20%28Q1%20FY2025%29) AngioDynamics reported Q1 FY2025 pro forma net sales of $67.5 million, driven by Med Tech growth, alongside a GAAP net loss of $12.8 million and an adjusted net loss of $4.4 million [Revenue Analysis](index=2&type=section&id=Revenue%20Analysis) Med Tech sales grew 8.7% to $28.0 million, driven by Auryon and AlphaVac, while Med Device sales declined 3.6% and international sales decreased significantly Q1 FY2025 Net Sales by Segment and Product | Segment / Product | Q1 FY2025 Sales | YoY Growth | | :--- | :--- | :--- | | **Med Tech** | **$28.0 million** | **8.7%** | | - Auryon | $13.7 million | 24.9% | | - AlphaVac | $2.2 million | 21.1% | | - NanoKnife | $5.1 million | (6.9)% | | **Med Device** | **$39.5 million** | **(3.6)%** | Q1 FY2025 Net Sales by Geography | Geography | Q1 FY2025 Sales | YoY Growth | | :--- | :--- | :--- | | U.S. Net Sales | $59.5 million | 6.2% | | International Net Sales | $8.0 million | (25.4)% | [Profitability Analysis](index=2&type=section&id=Profitability%20Analysis) Overall gross margin for Q1 FY2025 was 54.4%, a 40 basis point decrease, leading to a GAAP net loss of $12.8 million and an adjusted net loss of $4.4 million, despite an improved adjusted EBITDA Q1 FY2025 Gross Margin by Segment | Margin Metric | Q1 FY2025 | YoY Change | | :--- | :--- | :--- | | Overall Gross Margin | 54.4% | -40 bps | | Med Tech Gross Margin | 63.3% | -160 bps | | Med Device Gross Margin | 48.2% | -40 bps | Q1 FY2025 Profitability Summary | Profitability Metric | Q1 FY2025 | Q1 FY2024 | | :--- | :--- | :--- | | GAAP Net Loss | $(12.8) million | - | | GAAP Loss Per Share | $(0.31) | - | | Adjusted Net Loss | $(4.4) million | $(6.2) million | | Adjusted Loss Per Share | $(0.11) | $(0.16) | | Adjusted EBITDA | $(0.2) million | $(1.1) million | [Cash Flow and Balance Sheet](index=2&type=section&id=Cash%20Flow%20and%20Balance%20Sheet) AngioDynamics used $18.3 million in operating cash during Q1 FY2025, consistent with historical trends, resulting in $55.0 million in cash and cash equivalents as of August 31, 2024 - Used **$18.3 million** in operating cash during Q1 FY2025, consistent with historical trends for the first fiscal quarter[8](index=8&type=chunk) Cash and Cash Equivalents | Date | Cash and Cash Equivalents | | :--- | :--- | | August 31, 2024 | $55.0 million | | May 31, 2024 | $76.1 million | [Business & Clinical Updates](index=3&type=section&id=Business%20%26%20Clinical%20Updates) AngioDynamics achieved significant regulatory and clinical progress, including FDA submission for NanoKnife, European CE Mark for Auryon, and initiation of the RECOVER-AV clinical trial for AlphaVac - **NanoKnife System:** Submitted results from the PRESERVE pivotal study to the FDA for 510(k) clearance for the ablation of prostate tissue in intermediate-risk patients[10](index=10&type=chunk) - **Auryon System:** Received European CE Mark approval, allowing marketing in Europe for treating Peripheral Artery Disease (PAD) and expanding reach into a **$1.1 billion** global PAD market[11](index=11&type=chunk) - **AlphaVac System:** Initiated the RECOVER-AV clinical trial in Europe to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE), enrolling patients across up to 20 hospital sites[12](index=12&type=chunk) [Fiscal Year 2025 Financial Guidance](index=3&type=section&id=Fiscal%20Year%202025%20Financial%20Guidance) AngioDynamics reaffirmed its FY2025 financial guidance, projecting net sales between $282 to $288 million, driven by Med Tech growth, and an adjusted EBITDA loss between $0 and $2.5 million FY2025 Financial Guidance | Metric | FY2025 Guidance | | :--- | :--- | | Net Sales | $282 - $288 million | | Pro Forma Net Sales Growth | 4.2% - 6.4% | | Med Tech Net Sales Growth | 10% - 12% | | Med Device Net Sales Growth | 1% - 3% | | Gross Margin | 52% - 53% | | Adjusted EBITDA | $(2.5) million - $0 | | Adjusted Loss Per Share | $(0.38) - $(0.42) | [Financial Statements & Reconciliations](index=6&type=section&id=Financial%20Statements%20%26%20Reconciliations) Unaudited Q1 FY2025 financial statements, including Consolidated Income Statements, Balance Sheets, and Cash Flows, are presented with comprehensive GAAP to non-GAAP reconciliations [Consolidated Income Statements](index=6&type=section&id=Consolidated%20Income%20Statements) For Q1 FY2025, AngioDynamics reported net sales of $67.5 million, a gross profit of $36.7 million, an operating loss of $13.1 million, and a GAAP net loss of $12.8 million Q1 FY2025 Consolidated Income Statement Highlights | Income Statement (Q1 FY2025) | Amount (in thousands) | | :--- | :--- | | Net Sales | $67,491 | | Gross Profit | $36,724 | | Total Operating Expenses | $49,822 | | Operating Loss | $(13,098) | | Net Loss | $(12,798) | | Loss Per Share (Basic & Diluted) | $(0.31) | [Consolidated Balance Sheets](index=13&type=section&id=Consolidated%20Balance%20Sheets) As of August 31, 2024, total assets were $293.6 million, primarily due to a reduction in cash to $55.0 million, with total liabilities at $97.0 million and stockholders' equity at $196.6 million Consolidated Balance Sheet Highlights | Balance Sheet Item | Aug 31, 2024 (in thousands) | May 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $55,005 | $76,056 | | Total Current Assets | $172,594 | $193,253 | | Total Assets | $293,628 | $317,671 | | Total Liabilities | $97,046 | $112,085 | | Total Stockholders' Equity | $196,582 | $205,586 | [Consolidated Statements of Cash Flows](index=14&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For Q1 FY2025, net cash used in operating activities was $18.3 million, investing activities $2.4 million, and financing activities $0.5 million, resulting in a total cash decrease of $21.1 million Q1 FY2025 Consolidated Cash Flow Summary | Cash Flow Item (Q1 FY2025) | Amount (in thousands) | | :--- | :--- | | Net cash used in operating activities | $(18,253) | | Net cash used in investing activities | $(2,405) | | Net cash used in financing activities | $(509) | | **Increase (decrease) in cash** | **$(21,051)** | [Non-GAAP Reconciliations](index=7&type=section&id=Non-GAAP%20Reconciliations) Detailed reconciliations from GAAP to non-GAAP and pro forma figures are provided, showing an adjusted net loss of $4.4 million and an adjusted EBITDA loss of $163 thousand for Q1 FY2025 - Adjusted net loss for Q1 FY2025 was **$(4.4) million**, reconciled from a GAAP net loss of **$(12.8) million** by excluding items such as amortization of intangibles (**$2.6 million**) and acquisition/restructuring costs (**$4.3 million**)[22](index=22&type=chunk) - Pro forma adjusted diluted loss per share for Q1 FY2025 was **$(0.11)**, an improvement from **$(0.16)** in the prior-year period[28](index=28&type=chunk) - Pro forma adjusted EBITDA for Q1 FY2025 was **$(152) thousand**, compared to **$(1,072) thousand** in Q1 FY2024[30](index=30&type=chunk)

Core Insights - AngioDynamics, Inc. is expected to report a quarterly loss of 15 cents per share for its first quarter, compared to a loss of 12 cents per share in the same period last year [1] - Projected quarterly revenue for AngioDynamics is $67.93 million [1] - The company received CE Mark approval for its Auryon System in Europe on September 3 [1] - AngioDynamics shares closed at $7.65, reflecting a gain of 0.3% [1] Analyst Ratings - HC Wainwright analyst Yi Chen has a Buy rating with a price target of $14, with an accuracy rate of 63% [2] - Oppenheimer analyst Steven Lichtman upgraded the stock to Outperform with a price target of $12, having an accuracy rate of 74% [2] - Raymond James analyst Jayson Bedford maintained an Outperform rating but reduced the price target from $12 to $10, with an accuracy rate of 71% [2] Consensus Price Target - The consensus price target for AngioDynamics is $12.25 based on ratings from four analysts [3] - The highest price target is $14 from HC Wainwright & Co., while the lowest is $10 from Raymond James [3] - Recent analyst ratings suggest an implied upside of 75.21% for AngioDynamics based on an average price target of $13.67 [3]

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment based on earnings estimates [1] Company Summaries - **Marex Group plc (MRX)**: This financial services platform provider has seen a 22.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **AngioDynamics, Inc. (ANGO)**: This medical technology company has experienced a 12.8% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **Opera Limited (OPRA)**: This internet technology company has also seen a 12.8% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **Atour Lifestyle Holdings Limited (ATAT)**: This lifestyle hospitality company has had a 9.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - **Pampa Energía (PAM)**: This integrated power company has seen a 10.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1]

AngioDynamics, Inc.(ANGO) has initiated the RECOVER-AV clinical trial, a prospective, multinational, single-arm study aimed at assessing the efficacy, safety and long-term outcomes of the AlphaVac Multipurpose Mechanical Aspiration F1885 System for treating acute intermediate-risk pulmonary embolism (PE).Following the success of the U.S.-based APEX-AV trial, which demonstrated significant improvements in right ventricular function and clot burden reduction, RECOVER-AV will enroll patients across 20 European ...

Core Viewpoint - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment based on earnings estimates. Group 1: Company Summaries - Arcturus Therapeutics Holdings Inc. (ARCT) has seen a 40.8% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - M/I Homes, Inc. (MHO) has experienced an 8.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - First Mid Bancshares, Inc. (FMBH) has recorded a 7.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Pampa Energía (PAM) has seen a 13.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - AngioDynamics, Inc. (ANGO) has experienced a 31.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1]

AngioDynamics, Inc. (ANGO) has announced that its Auryon Atherectomy System has received the CE Mark. This innovative system, designed for the treatment of Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR), utilizes state-of-the-art solid-state laser technology. It stands out as the first laser atherectomy system capable of treating lesions of any type, length, or location with minimal vessel wall impact.AngioDynamics is a pioneering medical technology com ...

AngioDynamics (ANGO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ...

AngioDynamics (ANGO) closed the last trading session at $7.53, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.33 indicates a 77% upside potential.The average comprises three short-term price targets ranging from a low of $13 to a high of $14, with a standard deviation of $0.58. While the lowest estimate indicates an increase of 72.6% from the current price level, ...